177 Lutetium FPI 1835
Alternative Names: [177Lu]-FPI-1835; FPI-1835Latest Information Update: 10 Jun 2024
At a glance
- Originator Fusion Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
- 14 Apr 2023 Preclinical trials in Solid tumours in Canada (IV) (Fusion Pharmaceuticals pipeline, June 2023)
- 14 Apr 2023 Pharmacokinetics data from a preclinical trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)